ANTOINETTE BUSALACCHI: Open Payments
NPI 1518302124 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$331 in 16 payments from 8 companies in 2025. Trend: 2023 $34 · 2024 $441 · 2025 $331
Food & beverage: $331
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $65 |
| Madrigal Pharmaceuticals | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Eisai Inc. | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Exelixis Inc. | 1 | $17 |
| Eurofins Viracor, LLC | 1 | $14 |
Products named: PREVYMIS, XIFAXAN, REZDIFFRA, Lenvima, LIVTENCITY, EOHILIA, IQIRVO, CABOMETYX.
Industry payments across CA — which companies pay providers there.
